HDX-MS Plus Computational Methods Provide Novel Approach to Study of Protein-Protein Interactions

Why It Matters

Enhanced ELISA precision accelerates antibody candidate selection, reducing development timelines and costs. The technique also offers a scalable template for broader protein‑interaction research.

Key Takeaways

• HDX-MS combined with AI maps ELISA binding sites.
• Improves sandwich ELISA specificity and sensitivity.
• Enables rapid identification of antibody binding geometry.
• First use of HDX-MS for ELISA mechanism study.
• Facilitates preclinical antibody development decisions.

Pulse Analysis

Sandwich ELISA remains a cornerstone for quantifying antigens in complex biologics pipelines, yet its reliability hinges on antibodies binding distinct, non‑overlapping epitopes. Traditional assay optimization often involves trial‑and‑error, leading to prolonged development cycles and potential cross‑reactivity. By applying hydrogen‑deuterium exchange mass spectrometry, researchers can directly observe which protein regions are shielded during antibody interaction, offering a molecular‑level view of epitope accessibility that traditional methods cannot provide.

Regeneron's innovation lies in marrying HDX‑MS data with artificial‑intelligence‑driven computational modeling. The AI algorithms translate deuterium uptake patterns into three‑dimensional binding site maps, quantifying geometry and stoichiometry within hours. This synergy not only sharpens assay specificity but also enhances sensitivity, enabling detection of low‑abundance targets in preclinical pharmacokinetic studies. The rapid turnaround empowers scientists to redesign capture‑detection antibody pairs with confidence, cutting down on iterative testing and accelerating go‑to‑market timelines.

The broader implication for the biopharma sector is significant. A reproducible, high‑resolution method for dissecting protein‑protein interactions can be extended beyond ELISA to any platform requiring precise epitope characterization, such as bispecific antibody development or therapeutic protein engineering. As more organizations adopt HDX‑MS coupled with advanced analytics, the industry may see a shift toward data‑centric assay design, reducing costs and improving the predictive power of early‑stage drug candidates. This breakthrough positions Regeneron at the forefront of analytical innovation, setting a new standard for protein interaction studies.